Michelle Maynard

1.2k total citations
18 papers, 561 citations indexed

About

Michelle Maynard is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Michelle Maynard has authored 18 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 5 papers in Molecular Biology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Michelle Maynard's work include Cardiac Ischemia and Reperfusion (8 papers), Cardiac Arrest and Resuscitation (5 papers) and Cancer-related Molecular Pathways (3 papers). Michelle Maynard is often cited by papers focused on Cardiac Ischemia and Reperfusion (8 papers), Cardiac Arrest and Resuscitation (5 papers) and Cancer-related Molecular Pathways (3 papers). Michelle Maynard collaborates with scholars based in United States, United Kingdom and China. Michelle Maynard's co-authors include Peter Whittaker, Karin Przyklenk, Chad E. Darling, Rong Jiang, Jakob Vinten‐Johansen, Dale L. Greiner, Stephen A. Huang, Cuicui Guo, Huai‐Dong Song and Henry A. Feldman and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Michelle Maynard

16 papers receiving 551 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Maynard United States 10 385 244 200 113 108 18 561
Nilgün Gedik Germany 8 431 1.1× 267 1.1× 266 1.3× 75 0.7× 192 1.8× 10 607
Matthew Montgomery United States 9 213 0.6× 152 0.6× 75 0.4× 55 0.5× 335 3.1× 13 651
Zhi-Qing Zhao United States 12 321 0.8× 180 0.7× 87 0.4× 88 0.8× 98 0.9× 15 531
T Morioka Japan 9 249 0.6× 139 0.6× 87 0.4× 61 0.5× 131 1.2× 20 446
James Mykytenko United States 11 429 1.1× 282 1.2× 232 1.2× 109 1.0× 118 1.1× 14 578
Jinglin Zhao China 15 142 0.4× 69 0.3× 47 0.2× 160 1.4× 232 2.1× 55 511
B. C. G. Gho Netherlands 11 607 1.6× 392 1.6× 384 1.9× 133 1.2× 156 1.4× 22 786
Ahmar Ayub United States 8 289 0.8× 114 0.5× 95 0.5× 216 1.9× 102 0.9× 9 544
M. Kitakaze Japan 8 213 0.6× 91 0.4× 35 0.2× 116 1.0× 263 2.4× 9 503
Elena C. Lascano Argentina 14 136 0.4× 78 0.3× 54 0.3× 204 1.8× 299 2.8× 45 531

Countries citing papers authored by Michelle Maynard

Since Specialization
Citations

This map shows the geographic impact of Michelle Maynard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Maynard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Maynard more than expected).

Fields of papers citing papers by Michelle Maynard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Maynard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Maynard. The network helps show where Michelle Maynard may publish in the future.

Co-authorship network of co-authors of Michelle Maynard

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Maynard. A scholar is included among the top collaborators of Michelle Maynard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Maynard. Michelle Maynard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
Maynard, Michelle, et al.. (2022). Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders. 63. 103832–103832. 12 indexed citations
4.
House, Nealia C., Jian Guo, Ruduan Wang, et al.. (2022). Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models. Cancer Research. 82(12_Supplement). 2306–2306. 8 indexed citations
5.
Sherrard, Jackie, et al.. (2022). British Association for Sexual Health and HIV (BASHH) United Kingdom national guideline on the management of Trichomonas vaginalis 2021. International Journal of STD & AIDS. 33(8). 740–750. 7 indexed citations
6.
Rahal, Rami, Michelle Maynard, Wei Hu, et al.. (2018). Abstract B151: BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers. Molecular Cancer Therapeutics. 17(1_Supplement). B151–B151. 5 indexed citations
7.
Wassner, Ari J., David M. Dorfman, Robert F. Padera, et al.. (2017). Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy. Thyroid. 27(5). 732–737. 11 indexed citations
8.
Rahal, Rami, Erica N Evans, Wei Hu, et al.. (2016). Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors. Cancer Research. 76(14_Supplement). 2641–2641. 10 indexed citations
9.
Maynard, Michelle, Adrián Mariño‐Enríquez, Jonathan A. Fletcher, et al.. (2014). Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors. New England Journal of Medicine. 370(14). 1327–1334. 45 indexed citations
10.
Guo, Cuicui, Xia Chen, Huai‐Dong Song, et al.. (2014). Intrinsic Expression of a Multiexon Type 3 Deiodinase Gene Controls Zebrafish Embryo Size. Endocrinology. 155(10). 4069–4080. 28 indexed citations
11.
Przyklenk, Karin, Michelle Maynard, Dale L. Greiner, & Peter Whittaker. (2010). Cardioprotection with Postconditioning: Loss of Efficacy in Murine Models of Type-2 and Type-1 Diabetes. Antioxidants and Redox Signaling. 14(5). 781–790. 107 indexed citations
12.
Przyklenk, Karin, Michelle Maynard, Chad E. Darling, & Peter Whittaker. (2008). Aging Mouse Hearts Are Refractory to Infarct Size Reduction With Post-Conditioning. Journal of the American College of Cardiology. 51(14). 1393–1398. 108 indexed citations
13.
Przyklenk, Karin, Michelle Maynard, Dale L. Greiner, & Peter Whittaker. (2008). Abstract 1905: Restoration of Normoglycemia Re-Establishes the Infarct-Sparing Effect of Postconditioning in Diabetic Mice. Circulation. 118(suppl_18). 6 indexed citations
14.
Przyklenk, Karin, Michelle Maynard, Craig S. Smith, & Peter Whittaker. (2007). Abstract 546: Postconditioning Fails to Limit Infarct Size in the Setting of Type-2 and Type-1 Diabetes. Circulation. 116(suppl_16). 1 indexed citations
15.
Przyklenk, Karin, Michelle Maynard, & Peter Whittaker. (2006). First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. American Journal of Physiology-Heart and Circulatory Physiology. 291(4). H2008–H2012. 9 indexed citations
16.
Przyklenk, Karin, Michelle Maynard, & Peter Whittaker. (2005). Reduction of infarct size with d-myo-inositol trisphosphate: role of PI3-kinase and mitochondrial KATP channels. American Journal of Physiology-Heart and Circulatory Physiology. 290(2). H830–H836. 7 indexed citations
17.
Przyklenk, Karin, Michelle Maynard, Chad E. Darling, & Peter Whittaker. (2005). Pretreatment with d-myo-Inositol Trisphosphate Reduces Infarct Size in Rabbit Hearts: Role of Inositol Trisphosphate Receptors and Gap Junctions in Triggering Protection. Journal of Pharmacology and Experimental Therapeutics. 314(3). 1386–1392. 21 indexed citations
18.
Darling, Chad E., Rong Jiang, Michelle Maynard, et al.. (2005). Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. American Journal of Physiology-Heart and Circulatory Physiology. 289(4). H1618–H1626. 176 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nilgün Gedik Breakdown of academic impact, for papers by Matthew Montgomery Breakdown of academic impact, for papers by Zhi-Qing Zhao Breakdown of academic impact, for papers by T Morioka Breakdown of academic impact, for papers by James Mykytenko Breakdown of academic impact, for papers by Jinglin Zhao Breakdown of academic impact, for papers by B. C. G. Gho Breakdown of academic impact, for papers by Ahmar Ayub Breakdown of academic impact, for papers by M. Kitakaze Breakdown of academic impact, for papers by Elena C. Lascano
Rankless by CCL
2026